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Abstract
Prognosis of canine oral malignant melanoma encompasses clinical, histological and
immunohistochemical parameters. The aim of this study was to evaluate the prognos-
tic impact of bone invasion in oral canine melanoma. Sixty-eight dogs bearing oral
melanoma staged II and III that underwent surgery and anti-CSPG4 ele-
ctrovaccination, with available histological data and a minimum follow up of minimum
1 year, were retrospectively selected. Bone invasion was detected on imaging and/or
histology. Median survival time of dogs with evidence of bone invasion (group 1) was
397 days and significantly shorter compared with dogs with oral melanomas not
invading the bone (group 2, 1063 days). Dogs with tumours localised at the level of
the cheek, lip, tongue and soft palate (soft tissue - group 3) lived significantly longer
compared with dogs having tumours within the gingiva of the maxilla or mandible
(hard tissue - group 4) with a median survival time of 1063 and 470 days, respec-
tively. Within group 4, the subgroup of dogs with tumours not invading the bone
(group 5) showed a significant prolonged survival time (972 days) in comparison with
dogs of group 1 (bone invasion group). Similar results were obtained for the disease-
free intervals amongst the different groups. Statistical analysis showed that Ki67 and
mitotic count were correlated with shorter survival in patients of group 1 (with bone
invasion). Bone invasion should always be assessed since it appears to be a negative
prognostic factor.
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1 | INTRODUCTION
Malignant melanoma is the most frequent oral malignant tumour in
dogs accounting for 30%–40% of all canine oral malignancies.1–3 Sites
of primary growth are gingiva, internal lip/cheek, palate, tongue and
tonsil. Canine oral malignant melanoma (OMM) is an aggressive tumour
and it has been reported that its behaviour can be predicted by evaluat-
ing several clinical factors such as site of growth, size and clinical stage,
leukocytes ratio,2–5 and histological and immunohistochemical factors
such as Ki67 expression, mitotic count, degree of pigmentation,
nuclear atypia and platelet-derived growth factor receptor expres-
sion.6–8 The reported metastatic rate to regional lymph nodes and
distant sites such as lungs and other organs ranges from 30.3% to
74.0%3,9 and from 14.0% to 92.0%, respectively.3
The treatment of choice for local tumour control, if feasible, is wide
surgical excision, regardless of whether or not there is bone invasion at
presentation; the feasibility of an en bloc excision is influenced by both
the tumour location and the size of dog, as a minimum of 1.5–2 cm up
to 3 cm of macroscopically normal tissue all around the OMM should
be excised.1–3 Local tumour control is then surgically reached by also
performing a neck lymphadenectomy (mandibular and medial retro-
pharyngeal lymph nodes), ipsilaterally or bilaterally.10,11 The removal of
lymph nodes followed by histological evaluation also allows for com-
plete tumour staging, as lymph nodes with metastatic OMM may
appear clinically and cytologically normal.12,13 Radiotherapy should be
considered as an adjuvant treatment for OMMs that are incompletely
excised, as a primary treatment in combination with medical treat-
ment for those cases deemed inoperable or when the owners
refuse surgery.14–21 An alternative to radiotherapy for local tumour
control is electrochemotherapy, which may be contraindicated
when bone invasion is already evident.22–24 The results derived
from the addition of adjuvant chemotherapy (especially platinum-
based agents), to control the metastatic spread, has been disap-
pointing if compared to local tumour control only.16–18,25–27
Thanks to the immunogenic features of melanoma, several studies
dealing with immunotherapy have been recently carried out.
Melanoma-associated antigens have been identified (e.g., tyrosinase
and chondroitin sulphate proteoglycan 4 [CSPG4]) and utilized in pro-
ducing vaccines capable of evoking an immune response against
canine OMM.28–35 In particular, the authors' focus has been on
CSPG4, a cellular membrane antigen, characterised by restricted distri-
bution in normal healthy tissues and high expression on neoplastic
cells in both human and canine malignant melanoma. It coordinates
several intracellular pathways regulating different cell functions
(i.e., proliferation, migration and survival), thus being involved in
tumourigenesis at multiple levels.36–39 In addition, CSPG4 has also
been shown to be overexpressed in human melanoma cancer stem
cells and has been associated with poorer prognosis.32,40 All these fea-
tures make CSPG4 an ideal antigen to safely and effectively target. A
recent paper has shown the advantage of the combination of en bloc
excision plus adjuvant anti-CSPG4 vaccination in dogs with OMM.13
Bone invasion, as detected by advanced imaging and/or histologi-
cally, has been reported to occur in up to 57.0% of cases.3,41
However, its influence on prognosis remains to be clearly defined.
The aim of this study is to retrospectively evaluate the prognostic
impact of bone invasion in a population of dogs affected by stage II-III
OMMs locally controlled by surgery and treated adjuvantly with anti-
CSPG4 DNA electrovaccination.
2 | MATERIALS AND METHODS
2.1 | Patient selection and data collection
All dogs of this retrospective study were treated at the Teaching Veteri-
nary Hospital of Grugliasco (Turin) from 2010 to 2020. Dogs with con-
firmed OMM on histopathology, staged II-III, that underwent surgery
and adjuvant CSPG4 electrovaccination were eligible for entry into the
study. Specifically, only dogs bearing an OMM with an immunohisto-
chemical CSPG4 score ≥3/8 were considered as suitable candidates
for vaccination.40 Good Clinical Practise guidelines for animal clinical
studies were observed and both the Ethics Committee of the University
of Turin and the Italian Ministry of Health approved the study
(0004230-20/02/2018-DGSAF-MDS-P and 0015537-28/06/2017-
DGSAF-MDS-P). A written consent form was signed by the owners
before dogs' recruitment in the study.
Additional criteria for inclusion were a minimum follow-up of 1 year
on 1 April 2021, no concurrent life threatening disease and information
on the presence/absence of bone invasion based on imaging and/or his-
tology. Information retrieved from medical records for each dog
included age, sex, breed, body weight, tumour localization within the
oral cavity, tumour size and type of surgery performed. Pre-treatment
work-up consisted of physical examination, blood count, serum bio-
chemistry, cardiologic evaluation and urinalysis. Complete tumour stag-
ing was achieved by means of total body computed tomography
(CT scan) for the majority of cases. Alternatively, skull, three view chest
radiographs and abdominal ultrasound were obtained. The primary
tumour was resected by performing an en-bloc excision (man-
dibulectomy, maxillectomy, lip-cheek excision followed by reconstruc-
tion) with regional (ipsilateral or bilateral) lymphadenectomy.1–3 Dogs
were staged according to the World Health Organisation tumour/node/
distant metastases (TNM) guidelines as illustrated in Table 1.2,42
2.2 | Histological and immunohistochemical
analyses
Formalin-fixed paraffin-embedded (FFPE) samples of OMM were sta-
ined with haematoxylin-eosin for diagnosis according to the tumour
pathology guidelines.43 The following histological and immunohisto-
chemical data were recorded for all OMM samples: Ki67 expression
(polyclonal Ki67 antibody A-047; DAKO; cut-off of 19.5), mitotic
count in 10 high-power fields (MC; <4/10 high-power fields [hpf] or
≥4/10 hpf), nuclear atypia (quantification < or ≥ 30%), surgical mar-
gins infiltration status, presence of bone invasion, lymph node evalua-
tion and CSPG4 score.
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Immunohistochemistry (IHC) was performed on 4 mm thick paraffin
sections. After blocking peroxidase activity (0.3% H2O2 in deionised
water for 30 min) and heat-induced antigen retrieval (30 min with cit-
rate buffer at 98C, pH 6), sections were incubated with anti-Ki67 poly-
clonal antibody (Dako A-047; diluted 1:50) and anti-CSPG4 polyclonal
antibody (Sigma Aldrich; diluted 1:40). Detection was performed using
the Vector VIP Substrate kit for peroxidase (Vector Laboratories). In
case of amelanotic neoplasms, IHC with both Melan-A and PNL-2 anti-
bodies was also performed. Ki67 index was assessed according to the
methods previously reported by Bergin and colleagues. The previously
published threshold of 19.5 was used to predict prognosis.6 A total
score ranging from 0 to 8 was assigned to each melanoma sample by
adding the value that represented the proportion of CSPG4 positively
stained tumour cells (score from 0 to 5) and the average staining inten-
sity of CSPG4-positive tumour cells (score from 0 to 3).31,40
The presence of bone within the resection margins was not consid-
ered as an inclusion criterium as only the detection of bone invasion at
imaging and/or histology was evaluated in the study. Specifically, bone
infiltration at imaging was defined as minimal cortical disruption up to
advanced destruction of cortex involving the medullary bone in some
cases. Bone infiltration at histologywas reportedwhen tumoural cells were
found within the bone, together with a variable degree of bone destruc-
tion. Simple periosteal reaction at imaging was not considered as bone
invasion unless bone invasion was detected at histological examination.
2.3 | Patients' groups
First, all dogs were divided into two groups: group 1 (OMMs with bone
invasion) and group 2 (OMMs without bone invasion), regardless of
localization. Additionally, the total population was divided into two other
groups based on the site of growth and statistically evaluated. Patients
with OMMs at the level of cheek, lip, tonsil, soft palate and tongue were
included in group 3 (soft tissue group); patients with OMMs attached to
the gingiva of either the lower or upper dental arcade were included in
group 4 (hard tissue group). A subgroup of group 4, called group 5, con-
sisted of OMMs that were localised to the gingiva but did not invade the
bone. Thus, group 4 consisted of OMMs of group 1 (OMMs with bone
invasion) and OMMs of group 5 (no bone invasion). The DNA ele-
ctrovaccination procedure was performed in all the dogs of this study as
only OMMs characterised by a CSPG4 immunohistochemical expression
≥3/8 (cut-off value chosen for enrollment in the immunisation group)
were included.40 Dogs, under brief general anaesthesia, were vaccinated
with plasmids coding for the CSPG4 antigen. The vaccination was
started 1–3 weeks after surgery and was repeated after 2 weeks and
then monthly for a minimum of 6 and a maximum of 24 immunizations.
The CSPG4-coding plasmids (500 μg in 200 μl of 0.03% NaCl) were
injected into the muscles of the caudal thigh and, 2 min later, nine elec-
tric pulses were applied to the injection site using the CLINIPORATOR
(Igea), an instrument approved for veterinary application. The dogs were
monitored for acute, late local or systemic side effects.30–32
2.4 | Statistical analysis
The analyses were carried out using GraphPad Prism (version 9.0.0 for
Windows, GraphPad Software, San Diego, California, www.graphpad.
com), with statistical significance set at a p < .05. For statistical pur-
poses, the Shapiro–Wilk test was used to assess normality of distribu-
tion of the variables.
The DFI was calculated from the day of surgery to the first tumour
recurrence or metastasis while the MST was calculated as the period
from the day of surgery to the patient's death. DFI and MST were
analysed through generation of Kaplan–Meier curves; log-rank test was
used to compare DFI and MST of patients amongst different groups.
Dogs which died from non-COMM-related causes, those lost to follow-
up and those still alive at the end of the study were censored. Spe-
arman's correlation was used to look for association between MST and
MC or Ki67 of patients with and without bone invasion. Fisher's exact
test was used to test for possible association between different groups
and the probability of local recurrence and/or metastasis.
3 | RESULTS
3.1 | Signalment
Sixty-eight dogs fulfilled the inclusion criteria. There were 39 males
(23 intact, 16 castrated) and 29 females (5 intact, 24 spayed). The
mean and median age were 11.1 and 12 years (range, 6–14 years),
respectively; mean and median weight were 19.8 and 18 kg (range, 3–
40 kg), respectively. Twenty-one breeds were represented: 5 Cocker
Spaniels, 5 Golden Retrievers, 5 German Sheperd dogs, 4 Pinschers,
3 Pekingese, 3 Yorkshire Terriers, 2 Beagles, 2 Labrador Retrievers,
2 English bulldogs, 2 Dwarf Poodles, 2 Setters, 2 Shih Tzu dogs and
one of each of Jack Russell Terrier, Hovawart, Alaskan Malamute, Shar
Pei, Dwarf Schnauzer, Rottweiler, Spitz, Amstaff and West Highland
White Terrier. The remaining 22 dogs were crossbreeds.
3.2 | Staging and treatment
Clinical staging identified 38 stage II and 30 stage III OMMs; total
body CT scan was performed in 54 cases (79.4%) and chest and skull
TABLE 1 World Health Organization staging system for canine oral melanoma
Stage I Stage II Stage III Stage IV
≤2 cm diameter 2–4 cm diameter >4 cm diameter Any size
Negative lymph nodes Negative lymph nodes +/Metastatic lymph node Distant metastasis
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radiographs in conjunction with abdominal ultrasound in 14 cases
(20.6%). Tumour localization within the oral cavity of all patients is
shown in Table 2.
Twenty-four dogs underwent mandibulectomy (35.3%) and
14 maxillectomy (20.6%); en-bloc excision was performed in 14 dogs
(20.6%, 7 OMMs of the cheek and 7 OMMs of the lips) with or without
mucosal or skin flap reconstruction or a combination of both. Two dogs
(2.9%) underwent both mandibulectomy and en-bloc excision of the
cheek at the same time. One patient (1.5%) underwent tonsillectomy; a
simple excision was performed in 13 patients (19.1%) by the referring
veterinarian followed in two cases by a revision surgery. In the
remaining cases, surgical revision was not done due to the absence of
macroscopic and/or residual disease at clinical examination and staging.
Ipsilateral medial retropharyngeal lymphadenectomy was per-
formed in 55 dogs (80.9%), ipsilaterally in 39 dogs (70.9%) and bilat-
eral lymphadenectomy was performed in 16 dogs (29.1%). Ipsilateral
medial retropharyngeal lymph node was removed in 3 (7.7%) of the
39 dogs and bilaterally in 2 (1.2%) of the 16 dogs. In 13 dogs (19.1%)
the lymph node status was assessed for staging purposes only cyto-
logically after fine needle aspiration. In addition to surgery and immu-
notherapy, 5 dogs (7.3%) received electrochemotherapy (with
bleomycin intravenous injection) while 26 (38.2%) received metro-
nomic chemotherapy. This treatment consisted of low dose oral
administration of cyclophosphamide, piroxicam and thalidomide.
3.3 | Characterisation of the groups of dogs
The characterisation of the five groups of dogs is summarized in
Tables 3–5.
Local bone invasion was detected in 28 out of 68 OMMs (41.2%,
group 1). Of the entire population 34 out of 68 dogs (50%) had lymph
node metastasis. The lymph node metastatic rate in dogs of group
1 was 53.6% (15/28) while it was 47.5% (19/40) in group 2. Twenty-
six dogs were included in group 3 and 42 in group 4. The lymph node
metastatic rate was 53.8% (14/26) and 47.6% (20/42), respectively.
Fourteen dogs were included in group 5 and the lymph node meta-
static rate was 35.7% (5/14).
Regarding histological and immunohistochemical parameters,
Ki67 was <19.5 in 15/68 (22.1%) OMMs, >19.5 in 49/68 (72.1%)
OMMs, unknown in 3/68 (4.4%) and not detectable in one case, 1/68
(1.4%) because of the high pigmentation of the sample. The MC was
<4/10 hpf in 10/68 (14.7%) OMMs and ≥4/10 hpf in 58/68 (85.3%)
OMMs. Nuclear atypia was <30% in 11/68 (16.1%) OMMs, ≥30% in
52/68 (76.5%) OMMs and not available in 5/68 (7.4%) cases. Based
on histopathological of surgical margins, 38/68 (55.9%) OMMs were
determined to be completely excised, 21/68 (30.9%) were incom-
pletely excised, and the margin status could not be determined in
9/68 (13.2%) OMMs. Histological and immunohistochemical parame-
ters for every group are summarized in Table 6.
3.4 | Outcome and prognostic factors
Kaplan Meier curves were analysed for survival times and DFI. At the
end of the study, out of the 68 dogs, 7 dogs (10.3%) were still alive
(range 544–2815 days) and only one of these dogs (14.3%, 1/7) had
an OMM with bone invasion; 60 (88.2%) dogs were dead (range








Soft palate 1 (1.5%)
Tongue 3 (4.4%)
Tonsils 2 (2.9%)
Abbreviation: OMM, oral malignant melanoma.
TABLE 3 Characterisation of dogs in group 1 and group 2 based
on bone invasion
Overall patients Group 1 Group 2
(n = 68) (n = 28) (n = 40)
Presence of bone invasion 28 0
Absence of bone invasion 0 40




TABLE 4 Characterisation of dogs in group 3 and group 4 based
on localization of OMMs'
Overall patients Group 3 Group 4
(n = 68) (n = 26) (n = 42)
Hard tissue OMMs (gingiva of
mandible or maxilla)
0 42
Soft tissue OMMs (lip, cheek,
tongue tonsils and soft palate)
26 0




Abbreviation: OMM, oral malignant melanoma.
TABLE 5 Characterisation of dogs in group 1 and group 5 based
on bone invasion
Group 4 Group 1 Group 5
(n = 42) (n = 28) (n = 14)
Hard tissue OMMs (gingiva of mandible or maxilla)
Presence of bone invasion 28 0
Absence of bone invasion 0 14




Abbreviation: OMM, oral malignant melanoma.
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78–2155 days) and one (1.5%) was lost to follow up at 1178 days.
Thirty-seven dogs out of these 60 dogs (61.6%, 37/60) died of OMM-
related disease with 19 (51.3%, 19/37) of these displaying bone
invasion.
When groups' MSTs were compared, MST of group 1 (OMMs
with bone invasion) was 397 days (range 78–1951 days) while it
was 1063 days (range 172–2815 days) in group 2 (OMMs without
bone invasion), with a significant difference (p = .0006) (Figure 1A).
TABLE 6 Histological and immunohistochemical parameters of OMMs in each group
Threshold
Overall population Group 1 Group 2 Group 3 Group 4 Group 5
(n = 68) (n = 28) (n = 40) (n = 26) (n = 42) (n = 14)
Mitotic count <4/10 hpf 10 5 5 2 8 3
≥4/10 hpf 58 23 45 24 34 11
Ki67 <19.5 15 4 11 7 8 4
≥19.5 49 23 26 18 31 8
Unknown 4 1 3 1 3 2
<30% 11 3 8 6 5 2
Nuclear atypia ≥30% 52 25 27 17 35 10
Unknown 5 0 5 3 2 2
Margins Clear 38 17 21 16 22 7
Infiltrated 21 9 12 7 14 18
Unknown 9 2 7 3 6 1
Abbreviation: OMM, oral malignant melanoma.
(A)
(B)
F IGURE 1 Kaplan Meier analysis of (A) median survival time
(p= .0006) and (B) disease free interval (p= .004) of group 1 and group 2
(A)
(B)
F IGURE 2 Kaplan Meier analysis of (A) median survival time of
group 3 and group 4 (p = .0433) and (B) median survival time of group
1 and group 5 (p = .0357)
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The same significant result was evident for DFI; the DFI of group
1 was 193 days (range 29–782 days) and 470 days (range 13–
2815 days) for group 2 (p = .004) (Figure 1B). When group 3 (soft tis-
sue group) and group 4 (hard tissue group) were compared, MST of
group 3 was 1063 days (range 227–2815 days) and was significantly
longer (p = .004) than that of group 4 (470 days, range 78–2155 days)
(Figure 2A). Similar to MST, the DFI of group 3 (470 days, range 13–
2815 days) was longer than in group 4 (202 days, range
21–1681 days), although no statistical significance was found
(p = .115). When comparing dogs with OMMs of group 1 (bone inva-
sion) and group 5 (hard tissue OMMs without bone invasion), dogs of
group 5 had longer MSTs (972 days, range 172–2155 days, p = .035)
and DFIs (261 days, range 21–1681 days, p = .058) compared with
dogs of group 1 (MST 397 days, DFI 193 days) (Figure 2B). The MST
of the entire population was 653 days while DFI was 230 days.
No statistical association was found between groups 1 and 2, 3
and 4 or 1 and 5 in regard to occurrence of metastatic distant disease
and the incidence of local recurrence. Additionally, MST and Ki67
(p = .02, r = 0.43) and MC (p = .04, r = 0.39) were only signifi-
cantly correlated in group 1 (OMMs with bone invasion).
4 | DISCUSSION
In this study authors evaluate the impact of bone invasion in dogs
with canine OMMs in terms of DFI and MST amongst different groups
based on the presence/absence of bone invasion and OMM's localiza-
tion (hard vs. soft tissue). The presence/absence of bone invasion was
assessed only in dogs of the hard tissue group. All dogs were treated
with a multimodal approach by means of surgery and adjuvant anti-
CSPG4 vaccination. Some dogs also received metronomic chemother-
apy in addition to electrochemotherapy, in few cases. In addition, the
prognostic value of bone invasion, MC and Ki67 were evaluated in
this study.7
In recent years, several studies have aimed to identify prognostic
markers for melanocytic neoplasms. The prognostic impact of bone
invasion in canine OMM has been reported in very few studies and its
role remains to be clearly defined. Early studies found that the pres-
ence of bone lysis observed on skull radiographs in dogs with oral
melanoma did not significantly influence the survival time.44,45 In con-
trast, in another study evidence of bone lysis, recorded in 28% of the
cases, was significantly associated with a worse prognosis and time to
first event, which included tumour recurrence, regional or distant met-
astatic spread and death.15 In the Smedley et al. review, several prog-
nostic factors of melanocytic neoplasms were discussed, and the level
of invasion was divided into shallow infiltration with absence of bone
lysis associated with a favourable prognosis, and deep invasion with
bone lysis that negatively affected the patients' outcome7; the pro-
pensity of OMMs to invade locally, involving the bone in some cases,
might be due to the high vascular supply and lymphatic network of
the oral cavity that provides an optimal microenvironment for tumour
growth and metastatic invasion.46
Most of the dogs of this study underwent a curative intent sur-
gery to entirely remove the tumour, including at least 1.5 cm up to
3 cm of macroscopically normal bone, soft tissues or both (depending
on tumour localization)13; OMMs with bone invasion (group 1) were
characterised by reduced MST and DFI compared with dogs bearing
OMMs without bone invasion (group 2), with a significant difference
for both end points. Patients of group 3 (soft tissue) exhibited a signif-
icantly longer MST when compared with group 4 (hard tissue); the
same was true for the DFI, despite the lack of a significant difference.
The results of this study showed that when only considering dogs
with gingival OMMs (group 4, hard tissue), the subgroup that con-
sisted of dogs bearing OMMs without bone invasion (group 5) dis-
played a significantly prolonged MST compared with those of group
1 (bone invasion). However, there was no significant difference
regarding the DFI. The reason behind this group division was to evalu-
ate the impact of bone invasion more precisely in terms of prognosis.
It should also be noted that the evaluation of DFI of group 4 and
group 5, during the vaccination protocol, may not have been as accu-
rate, considering that these dogs were restaged with radiographs
instead of CT. The different diagnostic accuracy of the two techniques
could make the DFI a less reliable and precise end point. Additionally,
based on previous anti-CSPG4 electrovaccination studies, authors
reckon that the immunity induced by the vaccine is more effective in
reducing the development of distant metastatic disease rather than
local recurrence.31
A significant correlation was observed between Ki67, MC and
MST exclusively in dogs of group 1. This result might corroborate the
recognized prognostic value of Ki67 and MC, especially in OMMs
with bone invasion. As no specific numerical value was attributed to
nuclear atypia (which was ≥30% in 76.5% of samples) other than the
cut off < or ≥ 30%,7 no statistical correlation was assessed.
In this study, authors decided to include OMMs with evidence of
bone lysis detected on CT and/or histology; however, imaging and
histology might have some limitations in identifying this feature. On
one side, if the lysis process is in the early phase, CT scan might not
capture it because of the very superficial and slight remodelling at the
level of the bone surface. Additionally, 20% of our patients were
staged using radiographs which are less accurate compared with CT in
detecting bone invasion; in fact, it has been reported that bone lysis is
not evident on radiographs until 40% of the cortex is destroyed. This
suggests that CT scan is preferable for oral tumour staging.3,47,48 On
the other side, tumours including bone are trimmed for histological
evaluation through a cross-sectioning technique. In the case of wide
surgical margins, as they are in case of mandibulectomy or
maxillectomy, the cross-sectioning is performed through the cranial,
caudal, and central part of bone specimen.49 This may miss some
areas where bone lysis may be present; this problem should be over-
come with further sections, but this is not always feasible. Considering
these limitations, the bone invasion may have been underestimated in
this study.
Nevertheless, MST was prolonged compared with historically
reported survival times.18,50 This result may be partially attributable to
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the effect of the anti-CSPG4 electrovaccination.12,27,28 Several clinical
trials have been geared towards the use of DNA vaccination as a fun-
damental step in the management of malignant melanoma.13,28,29,51,52
Our protocol involves the electrovaccinaion against CSPG4, a class
one oncoantigen involved in several oncogenic pathways such as mel-
anoma tumour cell progression, survival and metastasis, and is poorly
expressed in healthy tissue. Therefore, CSPG4 has gained value as an
ideal immunotherapeutic target37–40; in recent and ongoing clinical tri-
als, anti-CSPG4 electrovaccination has revealed its potential thera-
peutic impact, being safe, immunogenic in inducing a significant
humoral response and effective in prolonging survival in OMM bear-
ing dogs.13,30,31 Based on previous and current results, authors reckon
that anti-CSPG4 electrovaccination is worthwhile to consider as
adjunct treatment considering its positive role in terms of outcome.
The lymph node metastatic rate did not significantly differ
between groups 1 and 2, although it was slightly higher in group
1. However, it is difficult to make any conclusions as different pro-
cedures were used to stage the lymph node status. Some dogs had
their lymph nodes evaluated only cytologically while others under-
went ipsilateral lymphadenectomy of mandibular and/or medial ret-
ropharyngeal lymph nodes, and only a few had a bilateral neck
lymphadenectomy. This limitation, together with the retrospective
nature of the study, may have led to underestimation of the
actual lymph node status in some patients. Recently, new surgical
procedures and methods have been proposed to improve lymph
node staging as part of the clinical staging based on the TNM
system.10,11,53–55
Regarding the localization of OMMs, the literature reports that
rostral tumours may be associated with a longer survival time.2,56,57
This can be explained by the fact that rostral tumours have a better
chance of being completely excised when compared to caudal
tumours. Additionally, because of their location, caudal malignant
tumours are often detected later in the course of the disease, having
already progressed to an advanced stage at the time of diagnosis.
Unfortunately, it was not feasible to evaluate OMMs of the present
canine population based on this detail because of the incompleteness
of data derived from both the retrospective nature of the study and
the different diagnostic procedures (CT scan vs. radiographs) used to
stage and therefore to detect bone invasion. Additionally, another
shortcoming of this study is the limited number of dogs included in
each group.
According to our data, bone invasion was significantly associated
with a shorter MST and a shorter DFI. The negative impact of bone
invasion was also evident when authors evaluated the MST and DFI
of dogs with OMMs of soft tissue and dogs with OMMs of hard tis-
sue, the latter group having a reduced MST and DFI.
In conclusion, several prognostic markers should be carefully eval-
uated for prognosis and treatment of OMM and this study further
supports that bone invasion is one of these factors. Because of its
negative impact on prognosis, bone invasion caused by canine OMM
should be assessed, if feasible, through an advanced diagnostic imag-
ing procedure and evaluated via histopathology.
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